Journals / Androloji Bülteni / 2023 / Cilt: 25 - Sayı: 2

Contraception and counseling for women with cardiovascular disease

Kardiyovasküler hastalığı olan kadınlarda kontrasepsiyon ve danışmanlık

Pages
127–134
Publication Date
2023-11-27
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The purpose of this review; To define contraceptive method options in women with cardiovascular heart disease, to examine the risks, benefits and contraceptive method medical eligibility criteria within the scope of counseling in line with the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The risk of maternal and neonatal morbidity and mortality is high in pregnancies of women that they have cardiovascular disease (CVD).
📊
Key Findings & Data:Despite the known risks of unplanned pregnancies, 25% to 54% of women with cardiovascular heart disease continue to have unplanned pregnancies.
💡
Conclusion & Impact:The purpose of this review; To define contraceptive method options in women with cardiovascular heart disease, to examine the risks, benefits and contraceptive method medical eligibility criteria within the scope of counseling in line with the literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The risk of maternal and neonatal morbidity and mortality is high in pregnancies of women that they have cardiovascular disease (CVD). Unplanned pregnancies are very risky if health cannot be optimized before conception. Despite the known risks of unplanned pregnancies, 25% to 54% of women with cardiovascular heart disease continue to have unplanned pregnancies. It is important to provide reliable contraception counseling and pregnancy planning before pregnancy to optimize the health of both mother and baby in this population. Early and accurate contraceptive counseling for women of reproductive age with cardiovascular heart disease is must to prevent unplanned pregnancies in this population. The purpose of this review; To define contraceptive method options in women with cardiovascular heart disease, to examine the risks, benefits and contraceptive method medical eligibility criteria within the scope of counseling in line with the literature.

Özet

Kardiyovasküler hastalığı (KVH) olan kadınların gebeliklerinde ma - ternal ve neonatal morbidite, mortalite riski yüksektir. Gebe kalma - dan önce sağlığın optimize edilememesi durumunda planlanmamış gebelikler oldukça risklidir. Planlanmamış gebeliklerin bilinen riskleri - ne rağmen, KVH’ı olan kadınların %25 ila %54’ünde planlanmamış gebelikler devam etmektedir. Bu popülasyonda hem annenin hem de bebeğin sağlığını optimize etmek için gebelik öncesi güvenilir kontra - sepsiyon danışmanlığı ve gebelik planlaması yapılması önemlidir. KVH’ı olan üreme çağındaki kadınlara erken ve doğru kontraseptif danışmanlık yapılması, bu populasyonda planlanmamış gebeliklerin önlenmesi için zorunludur. Bu derlemenin amacı; KVH’ı olan kadınlarda kontraseptif yöntem seçeneklerini tanımlamak, danışmanlık kapsamında riskleri, ya- rarları ve kontraseptif yöntem tıbbi uygunluk kriterlerini literatür doğ - rultusunda incelemektir.

🔖

Cite This Article

akgün, S., DAŞIKAN, Z. (2023). Contraception and counseling for women with cardiovascular disease. Androloji Bülteni, Cilt: 25 - Sayı: 2, 127–134. https://doi.org/10.24898/tandro.2023.66563

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Anderson KN, Tepper NK, Downing K, Ailes EC, Abarbanell G, Farr SL. Contraceptive methods of privately insured US women with congenital heart defects. Am Heart J. 2020
  2. 38–45. [CrossRef] 2. Lindley KJ, Bairey Merz CN, Davis MB, Madden T, Park K, Bello NA
  3. American College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group. Contraception and reproductive planning for women with cardiovascular disease: JACC Focus Seminar 5/5. J Am Coll Cardiol. 2021
  4. 1823–34. [CrossRef] 3. Okoth K, Chandan JS, Marshall T, Thangaratinam S, Thomas GN, Nirantharakumar K, Adderley NJ. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review [published correction appears in BMJ. 2020
  5. m3963. [CrossRef] 4. Fry KM, Gerhardt CA, Ash J, Zaidi AN, Garg V, McBride KL, Fitzgerald-Butt SM. Lifetime prevalence of sexual intercourse and contraception use at last sex among adolescents and young adults with congenital heart disease. J Adolesc Health. 2015
  6. 396–401. [CrossRef] 5. Abdalla M, Mancini DM. Management of pregnancy in the post cardiac transplant patient. Semin Perinatol. 2014
  7. 318–25. [CrossRef] 6. Maroo A, Chahine J. Contraceptive strategies in women with heart failure or with cardiac transplantation. Curr Heart Fail Rep. 2018
  8. 161–70. [CrossRef] 7. Faculty of Sexual & Reproductive Healthcare. UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: Faculty of Sexual & Reproductive Healthcare
  9. https://www. fsrh.org/standards-and-guidance/external/ukmec-2016-digital version/ 8. Jakes AD, Coad F, Nelson Piercy C. A review of contraceptive methods for women with cardiac disease. Obstet Gynaecol. 2018
  10. 21–9. [CrossRef] 9. Britton LE, Alspaugh A, Greene MZ, McLemore MR. CE. An evidence-based update on contraception. Am J Nurs. 2020
  11. 22– 33. [CrossRef] 10. Abarbanell G, Tepper NK, Farr SL. Safety of contraceptive use among women with congenital heart disease: a systematic review. Congenit Heart Dis. 2019
  12. 331–40. [CrossRef] 11. Lindley KJ, Madden T, Cahill AG, Ludbrook PA, Billadello JJ. Contraceptive use and unintended pregnancy in women with congenital heart disease. Obstet Gynecol. 2015
  13. 363–9. [CrossRef] 12. Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR. Contraception and cardiovascular disease. Eur Heart J. 2015
  14. 1728–34b. [CrossRef] 13. World Health Organization. Medical eligibility criteria for cont